Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations. The deal ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. | ...

Two groundbreaking studies challenge the traditional timeline of cat domestication, highlighting the pivotal influence of religious worship.